drugset / Trial / NCT03728933

A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause

NCT03728933

Phase 3 Terminated 23 enrolled UCB Biopharma SRL
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to demonstrate the efficacy of rotigotine against placebo in adolescent subjects with idiopathic Restless Legs Syndrome (RLS) over a 12-week maintenance period and to investigate the safety and tolerability of rotigotine in adolescent subjects with idiopathic RLS.

Timeline

Start
2018-12-20
Primary completion
2022-07-25
Completion
2022-07-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Rotigotine Unknown 2 mg Other
Subject Rotigotine Unknown 3 mg Other